US-based Banner Sun Health Research Institute and Banner Alzheimer’s Institute have initiated the clinical trial of the NeuroEM 1000 wearable head device to treat patients with Alzheimer’s Disease.
Developed by NeuroEM Therapeutics, the device is based on the company’s transcranial electromagnetic treatment (TEMT) to treat the entire brain.
TEMT breaks down the small protein aggregates (amyloid oligomers) found inside brain cells that are considered responsible for Alzheimer’s development in the brain.
TEMT then triggers an increased low-energy production of Alzheimer’s-diseased brain cells by enhancing their mitochondrial function since mitochondrial dysfunction is an early and critical symptom paving the development of the disease.
The technology is similar to the electromagnetic waves emitted by cell phones, exposure to which has been proven to facilitate beneficial cognitive changes to the EEG, increases brain energy production, and has no severe effects on health for a longer period of time.
NeuroEM Therapeutics president and CEO and developer of TEMT technology Dr Gary Arendash said: “We are very pleased to have two of the country’s most notable and trusted Alzheimer’s research institutes performing this first-of-its-kind clinical trial.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
“Although the Phase I trial is primarily to investigate safety of the TEMT head device, a number of measures have been included in the trial’s design that could provide evidence of therapeutic efficacy.”
TEMT involves interdigitated electric and magnetic waves that can easily make its way through the entire human brain to address the disease.
During the clinical trial, patients with AD will be treated with the NeuroEM 1000 head device at home which will be worn twice daily for one-hour treatments.
The treatment at home will not restrict normal mobility of the patient.
The trial is expected to be completed next year.